**Ortin Global Limited** (NSE: **ORTINGLOBE** | BSE: **539287**) is an Indian enterprise currently undergoing a radical structural and operational transformation. Formerly known as **Ortin Laboratories Limited**, the company has transitioned from a specialized pharmaceutical manufacturer to a diversified global trading and infrastructure entity. This shift follows a series of regulatory challenges in **2023**, leading to a complete overhaul of the company’s asset base, management control, and strategic mandate. --- ### **Strategic Pivot and Corporate Rebranding** Following the cancellation of its manufacturing license in **July 2023** for non-compliance with **Schedule-M** of the Drugs & Cosmetics Act, the company executed a "clean break" from its legacy operations. * **Name Change:** In **April 2024**, the company rebranded to **Ortin Global Limited** to signal its departure from laboratory-centric operations toward a broader global commerce model. * **Asset Liquidation:** To settle outstanding debts, the company received shareholder approval in **December 2023** to sell its land, buildings, and machinery at **Pashamylaram, Telangana**. It has since disposed of all **Property, Plant & Equipment (PPE)** (excluding vehicles) and liquidated obsolete manufacturing inventory. * **Operational Shift:** The company has moved to a **trading-focused model**, leveraging its existing market relationships to trade pharmaceutical formulations and chemicals rather than producing them. * **New Corporate Infrastructure:** In **July 2025**, the company established a new **Corporate Office** in the **Bandra Kurla Complex (BKC), Mumbai**, to serve as the hub for its domestic and international trading interests. --- ### **Management Change and 2026 Open Offer** As of **February 2026**, Ortin Global is undergoing a change in promoter control, which is expected to redefine its growth trajectory. * **The Acquirer:** **Mr. Parveen Satija** has entered into a Share Purchase Agreement (**SPA**) to acquire management control and will be designated as the new **Promoter**. * **Open Offer Terms:** A mandatory offer has been triggered to acquire up to **21,14,162 shares (26% of voting capital)** at a price of **₹14.65 per share**, representing a total commitment of **₹3.09 Crore**. * **Strategic Mandate:** The new management has committed to a **2-year moratorium** on alienating or restructuring significant assets (outside the ordinary course of business) while focusing on driving a "new growth phase" through the expanded business objects. --- ### **Diversified Business Verticals** The company’s amended **Memorandum of Association (April 2024)** allows for operations across three primary pillars: #### **1. Healthcare, Wellness & Consumer Goods** Ortin Global operates across the **Ayurvedic, Allopathic, Homeopathic, and Unani** systems. * **Pharmaceuticals:** Trading of **tablets, capsules, injections, tonics, and ointments**. * **Personal Care:** Production and distribution of toiletries (soaps, detergents, oral care) and cosmetics (beauty creams, perfumes, hair care). * **Wellness & Nutrition:** Focus on **herbal extracts, nourishment foods, concentrates, and juices**. * **Strategic Partnerships:** The company has secured distribution/trading footprints in India and the UAE through partnerships with global brands including **Disney, Hamleys, Miniso, and the Landmark Group**. #### **2. Real Estate and Infrastructure** The company has positioned itself as a full-cycle player in the property sector: * **Residential & Commercial:** Development of **townships, row-houses, shopping centers, and retail stores**. * **Civil Engineering:** Execution of large-scale infrastructure projects, including **National Highways and flyovers**. * **Industrial & Entertainment:** Construction of industrial complexes and cinema studios. #### **3. Global Trading and Mining** * **Commodity Trading:** Active in the trading of **ores, chemicals, spirits, and medicinal raw materials**. * **International Footprint:** In **November 2025**, the Board approved the incorporation of a Wholly Owned Subsidiary (WOS), **'ORTIN GLOBAL [DUBAI] FZ-LLC'**, in the UAE to facilitate Middle Eastern trade. --- ### **Financial Performance and Capital Structure** The company is currently in a recovery phase following a sharp contraction in its legacy business. | Metric (INR) | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Total Revenue** | **₹38.35 Lakhs** | **₹2.28 Crores** | | **Net Profit / (Loss)** | **(₹84.64 Lakhs)** | **(₹8.04 Crores)** | | **Reserves & Surplus** | **₹1.98 Crore** | **(₹5.30 Crore)** | | **Paid-up Equity Capital** | **₹8.13 Crores** | **₹8.13 Crores** | * **Revenue Dynamics:** Revenue declined by **83%** year-on-year as the company transitioned away from manufacturing. However, **Net Losses** narrowed significantly from **₹8.04 Crores** to **₹84.64 Lakhs**. * **Equity Details:** The capital base consists of **81,31,392 shares** (Face Value **₹10**). As of March 2025, **98.97%** of shares are held in dematerialized form. * **Debt Position:** The company carries **Non-Current Liabilities** of **₹3.35 Crores** and **Net Current Liabilities** of **₹6.98 Crores**. --- ### **Risk Profile and Compliance Monitor** #### **Financial & Operational Risks** * **Net Worth Erosion:** Auditors have noted that the company’s net worth has been **eroded by more than 50%**. * **Debt Recovery Actions:** In **February 2026**, authorized officers took possession of company property under the **SARFAESI Act** due to defaults on secured loans. * **Governance Lapses:** The company failed to appoint an **Internal Auditor** for **FY 2024-25** and experienced a vacancy in the **Company Secretary** role during early 2025. #### **Contingent Liabilities** | Nature | Period | Amount | Status | | :--- | :--- | :--- | :--- | | **GST Demands** | FY 2017-21 | **₹24.32 Crore** | Under Appeal; Management expects **₹70-80 Lakhs** actual impact. | | **TDS Notices** | FY 2008-24 | **₹1.88 Lakhs** | Outstanding. | #### **External Market Pressures** * **Regulatory & Industry:** The Indian pharmacy sector faces intense competition from **20 major organized players** and threats from **counterfeit drugs**. * **Macroeconomic:** New **US Global Tariffs (15%)** and changes to the **International Emergency Economic Powers Act (IEEPA)** effective **April 2025** may impact global trading margins. * **Forex/Commodity:** While currently reporting **no material exposure** due to the trading model, future international expansion via the Dubai WOS will reintroduce foreign exchange risks.